1. Circ Cardiovasc Interv
Comparison of Biolimus A9–Eluting (Nobori) and Everolimus-Eluting (Promus Element) Stents in Patients With De Novo Native Long Coronary Artery Lesions
by Jong-Young Lee, Duk-Woo Park, Young-Hak Kim, Jung-Min Ahn, Won-Jang Kim, Soo-Jin Kang, Seung-Whan Lee, Cheol Whan Lee, Seong-Wook Park, Sung-Cheol Yun, Tae-Hyun Yang, Bong-Ki Lee, Nae-Hee Lee, Joo-Young Yang, Won-Yong Shin, Hun Sik Park, Kee-Sik Kim, Seung Ho Hur, Sung Yun Lee, Jong-Seon Park, Yun Seok Choi, Seung Uk Lee, Sung-Ho Her, and Seung-Jung Park
Circ Cardiovasc Interv
Volume 7(3):
June 17, 2014
Copyright © American Heart Association, Inc. All rights reserved.

2. Patient flow and follow-up in the Long Drug-Eluting Stent (LONG-DES) V trial.
Patient flow and follow-up in the Long Drug-Eluting Stent (LONG-DES) V trial. No reliable data are available on the assessment criteria for patient eligibility.
Jong-Young Lee et al. Circ Cardiovasc Interv. 2014;7:
Copyright © American Heart Association, Inc. All rights reserved.

3. Cumulative rates of in-segment late luminal loss at follow-up angiography.
Cumulative rates of in-segment late luminal loss at follow-up angiography. Late luminal loss was defined as the difference between the minimal luminal diameter at the end of the procedure and the minimal luminal diameter at follow-up.
Jong-Young Lee et al. Circ Cardiovasc Interv. 2014;7:
Copyright © American Heart Association, Inc. All rights reserved.

4. Kaplan–Meier 12-month actuarial incidence of major adverse cardiac events.
Kaplan–Meier 12-month actuarial incidence of major adverse cardiac events. Major adverse cardiac events were defined as the composite of death, myocardial infarction, or ischemia-driven target vessel revascularization.
Jong-Young Lee et al. Circ Cardiovasc Interv. 2014;7:
Copyright © American Heart Association, Inc. All rights reserved.